专利检索 ap:("ONO PHARMACEUTICAL CO., LTD.") AND inv:"Tatsuya OKAMOTO" 第 1 页

1.

发明公开
CANCER TREATMENT METHOD BY COMBINED USE OF CD47 INHIBITORY SUBSTANCE, IMMUNE CHECKPOINT INHIBITORY SUBSTANCE, AND STANDARD THERAPY 审中-公开

公开(公告)号：US20240254226A1

公开(公告)日：2024-08-01

申请号：US18566424

申请日：2022-06-09

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Tatsuya OKAMOTO

IPC分类号： C07K16/28 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/555 , A61K39/00 , A61P35/00

CPC分类号： C07K16/2803 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/555 , A61P35/00 , A61K2039/507 , A61K2039/545

摘要： An effective cancer treatment method is disclosed. According to the cancer treatment method, a CD47 inhibitory substance, an immune checkpoint inhibitory substance (for example, an anti-PD-1 antibody), and a standard therapy (for example, a combination therapy in which Bevacizumab or Cetuximab is added to FOLFOX therapy for radically unresectable advanced or recurrent colorectal cancer, or FOLFIRINOX therapy or a dose-reduced regimen thereof for pancreatic cancer having distant metastasis) are combined. The treatment method is useful for cancer treatment.